---
layout: post
title: "Prospective Grant of an Exclusive Patent License: Development and Commercialization of Caspase Inhibitors"
date: 2026-02-05 18:56:11 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-15445
original_published: 2023-07-21 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of an Exclusive Patent License: Development and Commercialization of Caspase Inhibitors

**Published:** February 05, 2026 18:56 UTC
**Source:** Federal Register
**Original Published:** July 21, 2023 00:00 UTC
**Document Number:** 2023-15445

## Summary

The National Center for Advancing Translational Sciences, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this Notice to Elgia Therapeutics Inc. ("Elgia"), headquartered in La Jolla, CA.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/07/21/2023-15445/prospective-grant-of-an-exclusive-patent-license-development-and-commercialization-of-caspase)
- API: https://www.federalregister.gov/api/v1/documents/2023-15445

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
